KBI has a large colony of obese NHP models readily available for the needs of research services. 

We routinely evaluate anti-obese efficacy with a wide range of tools including the following techniques:

·  measurements of caloric intake and body mass index (BMI) 

·  quantification of body fat composition with dual energy X-ray absorptiometry (DEXA and iDXA) 

·  measurement of ectopic fat accumulation with magnetic resonance imaging (MRI)  

·  molecular biomarkers (such as adipokine mRNA expression) from fat biopsy in the area of interest

Further, we have successfully provided successful services for the evaluation of anti-obese drugs with associated diseases at different stages including:

·  dyslipidemia (including triglyceride, cholesterol, LDL-C, HDL-C and lipoproteins) 

·  pre-diabetes, diabetes and diabetic complications (such as diabetic chronic kidney disease)

·  non-alcoholic fatty liver disease 

·  cardiovascular disease (such as hypertension and heart failure)